Global Insights on Implantable Cardioverter-Defibrillators in High-Risk Hypertrophic Cardiomyopathy: Efficacy and Outcomes
Highlight
This large-scale, international study involving over 3300 patients with hypertrophic cardiomyopathy (HCM) demonstrates that implantable cardioverter-defibrillators (ICDs) effectively prevent sudden cardiac death by terminating life-threatening ventricular arrhythmias. Key findings include a 16% event rate of appropriate ICD therapies, low device failure rates, and high survival free from HCM-related mortality over two decades.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.